Table 1 Baseline demographic and laboratory characteristics.

From: Renal protective effect of sacubitril/valsartan in patients with heart failure

Characteristics Total Sacubitril/valsartan Valsartan P value
n = 274 n = 137 n = 137
Male, n(%) 180(65.7) 90(65.7) 90(65.7) 1.00
Age, years 72.7 ± 14.9 72.7 ± 14.9 72.7 ± 14.9 0.98
DM, n(%) 116(42.3) 51(37.2) 65(47.5) 0.89
Hypertension, n(%) 274(100) 137(100) 137(100) 1.00
AFib, n(%) 54(19.7) 34(24.8) 20(14.6) 0.03
HF-related hospitalization, n(%) 49(17.9) 40(29.2) 9(6.6) < 0.01
BUN, mg/dL 22(12) 22(12) 21(13) 0.52
Cr, mg/dL 1.0(0.4) 1.0(0.4) 1.0(0.5) 0.85
eGFR, mL/min/1.73 m2 70.9 ± 24.7 70.9 ± 24.6 71.0 ± 24.9 0.97
eGFR groups, n     
≥ 60 190 95 95 n/a
< 60 to ≥ 30 to 72 36 36 n/a
< 30 12 6 6 n/a
AST, U/L 20(10) 20(7) 20(9) 0.30
ALT, U/L 18(12) 18(12) 18(12) 0.85
Hemoglobin, g/dL 12.8(2.9) 12.9(2.8) 12.7(2.9) 0.97
K, mmol/L 4.2(0.7) 4.2(0.6) 4.1(0.8) 0.01
WBC, 103/uL 7.7 (3.7) 7.2(3.8) 7.7(4.0) 0.06
  1. DM diabetes mellitus, AFib atrial fibrillation, HF heart failure, BUN blood urea nitrogen, Cr creatinine, eGFR estimated glomerular filtration rate, AST aspartate transaminase, ALT alanine transaminase, WBC, white blood cell.